Product Watch: Enzymatics Sarcoma Fusion Assay | GenomeWeb

Enzymatics this week launched a targeted sequencing assay today for detecting and identifying fusions of 26 genes associated with sarcoma.

Using Enzymatics' proprietary anchored multiplex PCR-based enrichment, fusions of all genes in their panel can be identified in a single sequencing run, even without prior knowledge of fusion partners or breakpoints, the company said. The assay will join the ALK, RET, ROS1 v2 panel and the Heme panel as the newest addition to the Archer FusionPlex product line.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.